Oxidative_JJ Stress_NP Increases_NNS Susceptibility_NN of_IN Mycobacterium_NN tuberculosis_NN to_TO Isoniazid_NP Isoniazid_NP is_VBZ a_DT first-line_NN antibiotic_NN used_VBN in_IN the_DT treatment_NN of_IN infections_NNS caused_VBN by_IN Mycobacterium_NN tuberculosis_NN ._SENT Isoniazid_NN is_VBZ a_DT prodrug_NN requiring_VBG oxidative_JJ activation_NN by_IN the_DT catalase-peroxidase_NN hemoprotein_NN ,_, KatG_NP ._SENT Resistance_NN to_TO isoniazid_NN can_MD be_VB obtained_VBN by_IN point_NN mutations_NNS in_IN the_DT katG_NN gene_NN ,_, with_IN one_CD of_IN the_DT most_RBS common_JJ being_VBG a_DT threonine-for-serine_JJ substitution_NN at_IN position_NN 315_CD (_( S315T_NP )_) ._SENT The_DT S315T_NP mutation_NN is_VBZ found_VBN in_IN more_JJR than_IN 50_CD %_NN of_IN isoniazid-resistant_JJ clinical_JJ isolates_NNS and_CC results_NNS in_IN an_DT ~200-fold_NN increase_NN in_IN the_DT MIC_NN of_IN isoniazid_NN compared_VBN to_TO that_DT for_IN M._NP tuberculosis_NN H37Rv_NP ._SENT In_IN the_DT present_JJ study_NN we_PP investigated_VBD the_DT hypothesis_NN that_IN superoxide_NN plays_VBZ a_DT role_NN in_IN KatG-mediated_NP isoniazid_NN activation_NN ._SENT Plumbagin_NP and_CC clofazimine_NN ,_, compounds_NNS capable_JJ of_IN generating_VBG superoxide_NN anion_NN ,_, resulted_VBN in_IN a_DT lower_JJR MIC_NN of_IN isoniazid_NN for_IN M._NP tuberculosis_NN H37Rv_NP and_CC a_DT strain_NN carrying_VBG the_DT S315T_NP mutation_NN ._SENT These_DT agents_NNS did_VBD not_RB cause_VB as_RB great_JJ of_IN an_DT increase_NN in_IN isoniazid_NN susceptibility_NN in_IN the_DT mutant_JJ strain_NN when_WRB the_DT susceptibilities_NNS were_VBD assessed_VBN by_IN using_VBG the_DT inhibitory_JJ concentration_NN that_WDT causes_VBZ a_DT 50_CD %_NN decrease_NN in_IN growth_NN ._SENT These_DT results_NNS provide_VBP evidence_NN that_IN superoxide_NN can_MD play_VB a_DT role_NN in_IN isoniazid_NN activation_NN ._SENT Since_IN clofazimine_NN alone_RB has_VBZ antitubercular_JJ activity_NN ,_, the_DT observation_NN of_IN synergism_NN between_IN clofazimine_NN and_CC isoniazid_NN raises_VBZ the_DT interesting_JJ possibility_NN of_IN using_VBG both_DT drugs_NNS in_IN combination_NN to_TO treat_VB M._NP tuberculosis_NN infections_NNS ._SENT Entering_VBG the_DT 21st_JJ century_NN ,_, Mycobacterium_NN tuberculosis_NN ,_, the_DT causative_JJ agent_NN of_IN tuberculosis_NN (_( TB_NN )_) ,_, remains_VBZ a_DT major_JJ cause_NN of_IN morbidity_NN and_CC mortality_NN worldwide_RB ._SENT TB_NN causes_VBZ 1.9_CD million_CD deaths_NNS annually_RB among_IN a_DT pool_NN of_IN infected_JJ individuals_NNS close_JJ to_TO 2_CD billion_NN people_NNS ._SENT Isoniazid_NN (_( INH_NP )_) is_VBZ one_CD of_IN the_DT most_RBS effective_JJ and_CC widely_RB used_VBN therapeutic_JJ agents_NNS for_IN the_DT treatment_NN of_IN TB_NN ._SENT M._NP tuberculosis_NN shows_VBZ exceptional_JJ sensitivity_NN to_TO INH_NP ,_, being_VBG several_JJ orders_NNS of_IN magnitude_NN more_RBR sensitive_JJ than_IN most_RBS other_JJ bacterial_JJ species_NNS ._SENT Much_RB is_VBZ known_VBN about_IN the_DT mechanism_NN of_IN INH_NP activation_NN ,_, including_VBG that_DT fact_NN that_IN it_PP is_VBZ a_DT prodrug_NN requiring_VBG activation_NN by_IN the_DT catalase-peroxidase_NN hemoprotein_NN ,_, KatG_NP ,_, in_IN a_DT process_NN that_WDT requires_VBZ molecular_JJ oxygen_NN ._SENT It_PP has_VBZ been_VBN further_RBR shown_VBN that_IN the_DT activated_VBN form_NN of_IN INH_NP forms_VBZ a_DT covalent_JJ adduct_VB with_IN NAD+_NP to_TO generate_VB a_DT potent_JJ inhibitor_NN of_IN the_DT InhA_NP protein_NN of_IN M._NP smegmatis_NP ,_, an_DT enoyl-acyl_NN carrier_NN protein_NN reductase_NN important_JJ in_IN mycolic_JJ acid_JJ biosynthesis_NN ._SENT Recent_JJ investigations_NNS have_VBP led_VBN to_TO the_DT hypothesis_NN that_IN the_DT sensitivity_NN of_IN M._NP tuberculosis_NN to_TO INH_NP may_MD be_VB governed_VBN by_IN the_DT level_NN of_IN expression_NN of_IN the_DT alkyl_NN hydroperoxide_NN reductase_NN ,_, AhpC_NP ,_, since_IN M._NP tuberculosis_NN does_VBZ not_RB express_VB the_DT ahpC_NN gene_NN due_JJ to_TO inactivation_NN of_IN the_DT oxidative_JJ stress_NN regulatory_JJ gene_NN oxyR_NN ._SENT Nevertheless_RB ,_, specific_JJ details_NNS regarding_VBG the_DT mechanism_NN of_IN action_NN of_IN INH_NP ,_, such_JJ as_IN the_DT chemical_JJ nature_NN of_IN the_DT activated_VBN form_NN of_IN INH_NP ,_, have_VBP yet_RB to_TO be_VB determined_VBN ._SENT For_IN example_NN ,_, InhA_NP as_IN the_DT primary_JJ target_NN for_IN INH_NP in_IN M._NP tuberculosis_NN has_VBZ been_VBN questioned_VBN following_VBG the_DT discovery_NN of_IN a_DT covalent_JJ complex_NN of_IN INH_NP ,_, acyl_NN carrier_NN protein_NN (_( AcpM_NP )_) ,_, and_CC the_DT beta-ketoacyl_NN acyl_NN carrier_NN protein_NN synthase_NN ,_, KasA_NP ._SENT Rates_NNS of_IN resistance_NN to_TO INH_NP and_CC other_JJ antibiotics_NNS have_VBP been_VBN increasing_VBG such_JJ that_IN now_RB approximately_RB 13_CD %_NN of_IN all_DT TB_NN cases_NNS in_IN the_DT United_NP States_NPS are_VBP resistant_JJ to_TO at_IN least_JJS one_CD first-line_NN drug_NN (_( INH_NP ,_, rifampin_NN ,_, pyrazinamide_NN ,_, ethambutol_NN ,_, and_CC streptomycin_NN )_) ._SENT INH-resistant_NP M._NP tuberculosis_NN has_VBZ been_VBN associated_VBN with_IN deletions_NNS or_CC point_NN mutations_NNS in_IN the_DT katG_NN gene_NN ,_, with_IN the_DT threonine-for-serine_JJ substitution_NN at_IN position_NN 315_CD (_( S315T_NP )_) in_IN katG_NN being_VBG one_CD of_IN the_DT most_RBS common_JJ mutations_NNS found_VBN in_IN clinical_JJ isolates_NNS ._SENT A_DT comparison_NN of_IN M._NP tuberculosis_NN KatG_NP with_IN cytochrome_NN c_NN peroxidase_NN ,_, a_DT member_NN of_IN the_DT same_JJ catalase-peroxidase_NN superfamily_NN ,_, suggests_VBZ that_IN S315_NP occupies_VBZ a_DT position_NN near_IN the_DT active_JJ site_NN of_IN KatG_NP ,_, and_CC therefore_RB ,_, the_DT S315T_NP mutation_NN could_MD affect_VB the_DT enzymatic_JJ activity_NN of_IN KatG_NP ._SENT Besides_IN exhibiting_VBG catalase_NN and_CC peroxidase_NN activities_NNS ,_, several_JJ other_JJ enzymatic_JJ activities_NNS have_VBP been_VBN associated_VBN with_IN M._NP tuberculosis_NN KatG_NP ,_, including_VBG Mn(II)-dependent_JJ peroxidase_NN ,_, peroxynitritase_NN ,_, and_CC cytochrome_NN P450-like_JJ monooxygenase_NN activities_NNS ._SENT The_DT KatG_NP protein_NN and_CC the_DT KatG_NP protein_NN with_IN the_DT S315T_JJ mutation_NN [_SYM KatG(S315T)_NP ]_SYM have_VB comparable_JJ catalase_NN and_CC peroxidase_NN activities_NNS ,_, and_CC KatG(S315T)_NP is_VBZ able_JJ to_TO oxidize_VB INH_NP at_IN equivalent_JJ rates_NNS using_VBG a_DT hydroperoxide_NN as_IN oxidant_NN ,_, suggesting_VBG that_IN the_DT peroxidase_NN activity_NN of_IN KatG_NP may_MD not_RB be_VB relevant_JJ for_IN the_DT in_IN vivo_JJ activation_NN of_IN INH_NP ._SENT In_IN the_DT presence_NN of_IN dioxygen_NN but_CC the_DT absence_NN of_IN a_DT hydroperoxide_NN ,_, INH_NP is_VBZ oxidized_VBN more_RBR slowly_RB by_IN KatG(S315T)_NP than_IN by_IN KatG_NP ,_, a_DT phenomenon_NN that_WDT has_VBZ been_VBN shown_VBN to_TO involve_VB superoxide_NN and_CC that_WDT may_MD reflect_VB why_WRB the_DT S315T_NP mutation_NN confers_VBZ INH_NP resistance_NN ._SENT Superoxide_NN is_VBZ formed_VBN during_IN INH_NP oxidation_NN and_CC is_VBZ thought_VBN to_TO be_VB involved_VBN in_IN the_DT activation_NN process_NN (_( -_: )_) ._SENT INH_NP oxidation_NN via_IN this_DT route_NN is_VBZ thought_VBN to_TO involve_VB a_DT monooxygenase_NN pathway_NN in_IN which_WDT an_DT oxyferrous_JJ KatG_NP intermediate_NN is_VBZ formed_VBN by_IN either_DT dioxygen_NN binding_VBG to_TO ferrous_JJ KatG_NN or_CC superoxide_NN binding_VBG to_TO ferric_JJ KatG_NP ._SENT These_DT biochemical_JJ observations_NNS support_VBP the_DT hypothesis_NN that_IN a_DT mechanism_NN other_JJ than_IN the_DT catalase-peroxidase_NN route_NN plays_VBZ an_DT important_JJ role_NN in_IN INH_NP resistance_NN ._SENT Direct_JJ evidence_NN for_IN this_DT was_VBD provided_VBN by_IN Drlica_NP and_CC colleagues_NNS ,_, who_WP showed_VBD that_IN the_DT superoxide_NN generator_NN plumbagin_NP resulted_VBD in_IN an_DT increase_NN in_IN the_DT bacteriostatic_JJ activity_NN of_IN INH_NP against_IN M._NP smegmatis_NP ,_, a_DT strain_NN normally_RB resistant_JJ to_TO INH_NP ._SENT In_IN the_DT study_NN described_VBN in_IN this_DT report_NN we_PP tested_VBD the_DT hypothesis_NN that_IN superoxide_NN plays_VBZ a_DT role_NN in_IN KatG-mediated_NP INH_NP oxidation_NN in_IN M._NP tuberculosis_NN ._SENT Radiometric_JJ analyses_NNS were_VBD conducted_VBN to_TO determine_VB MICs_NP and_CC the_DT inhibitory_JJ concentrations_NNS of_IN drug_NN that_WDT cause_VBP a_DT 50_CD %_NN decrease_NN in_IN strain_NN growth_NN (_( IC50s_NP )_) of_IN INH_NP alone_RB and_CC INH_NP in_IN combination_NN with_IN superoxide-generating_VBG substances_NNS ,_, plumbagin_NP or_CC clofazimine_NP ,_, for_IN an_DT INH-sensitive_JJ M._NP tuberculosis_NN strain_NN and_CC an_DT INH-resistant_JJ strain_NN containing_VBG the_DT katG_NN S315T_NP mutation_NN ._SENT Bacterial_JJ strains_NNS ._SENT |_SYM The_DT M._NP tuberculosis_NN strains_NNS used_VBN in_IN this_DT study_NN ,_, strains_VBZ H37Rv_NP and_CC TBC3_NP ,_, were_VBD grown_VBN on_IN Middlebrook_NP 7H10_NP slants_VBZ at_IN 37C_JJ ._SENT TBC3_NP is_VBZ an_DT INH-resistant_JJ clinical_JJ isolate_NN ._SENT Drugs_NNS and_CC reagents_NNS ._SENT |_SYM Dimethyl_NP sulfoxide_NP (_( DMSO_NP )_) ,_, INH_NP ,_, clofazimine_NN ,_, and_CC plumbagin_NP (_( technical_JJ grade_NN )_) were_VBD purchased_VBN from_IN Sigma_NP Chemical_NP Co._NP (_( St._NP Louis_NP ,_, Mo._NP )_) ;_: shrimp_VB alkaline_JJ phosphatase_NN and_CC exonuclease_NN I_PP were_VBD provided_VBN by_IN U.S._NP Biochemicals_NP (_( Cleveland_NP ,_, Ohio_NP )_) ._SENT INH_NP was_VBD recrystallized_VBN from_IN boiling_VBG methanol_NN by_IN using_VBG activated_VBN charcoal_NN decolorization_NN and_CC hot_JJ filtration_NN through_IN Whatman_NP no_RB ._SENT 1_CD filter_NN paper_NN (_( Whatman_NP International_NP Ltd._NP ,_, Maidstone_NP ,_, United_NP Kingdom_NP )_) ._SENT The_DT crystals_NNS were_VBD vacuum_NN filtered_VBN ,_, washed_VBN with_IN ice-cold_JJ methanol_NN ,_, and_CC air_NN dried_VBD ,_, yielding_VBG white_JJ needles_NNS with_IN a_DT melting_VBG point_NN of_IN 172C_NP ._SENT INH_NP was_VBD dissolved_VBN in_IN water_NN and_CC filter_NN sterilized_VBN through_IN a_DT 0.22-mum-pore-size_JJ filter_NN ._SENT For_IN stock_NN solutions_NNS of_IN clofazimine_NN (_( 16.9_CD muM_NN )_) and_CC plumbagin_NP (_( 1.6_CD mM_NNS )_) ,_, 4_CD %_NN DMSO_NP was_VBD used_VBN as_IN the_DT solvent_NN ._SENT Appropriate_JJ controls_NNS were_VBD included_VBN to_TO ensure_VB that_IN the_DT inhibitory_JJ effects_NNS of_IN the_DT drugs_NNS were_VBD not_RB due_JJ to_TO the_DT addition_NN of_IN DMSO_NP ,_, although_IN there_EX are_VBP data_NNS indicating_VBG that_IN this_DT solvent_NN enhances_VBZ the_DT potencies_NNS of_IN the_DT drugs_NNS ._SENT DNA_NP sequencing_NP and_CC sequence_NN analysis_NN ._SENT |_SYM The_DT presence_NN of_IN a_DT wild-type_NN katG_NN gene_NN in_IN strain_NN H37Rv_NP and_CC a_DT katG_NN gene_NN harboring_VBG the_DT S315T_NP mutation_NN in_IN strain_NN TBC3_NP was_VBD confirmed_VBN by_IN restriction_NN fragment_NN length_NN polymorphism_NN analysis_NN ._SENT Sequencing_VBG of_IN the_DT DNA_NN of_IN the_DT entire_JJ katG_NN gene_NN from_IN TBC3_NP was_VBD also_RB carried_VBN out_RP to_TO confirm_VB the_DT presence_NN of_IN the_DT S315T_NP mutation_NN and_CC the_DT absence_NN of_IN secondary_JJ mutations_NNS ._SENT Briefly_RB ,_, the_DT katG_NN gene_NN was_VBD amplified_VBN by_IN PCR_NP ,_, and_CC the_DT genomic_JJ DNA_NN was_VBD isolated_VBN from_IN TBC3_NP ._SENT Genomic_NP DNA_NP was_VBD isolated_VBN by_IN inoculating_VBG a_DT 10-mul_NP loopful_NN of_IN a_DT culture_NN into_IN a_DT tube_NN containing_VBG 100_CD mul_NN of_IN water_NN ._SENT Approximately_RB 2_CD ml_NN of_IN alkaline_JJ wash_NN solution_NN (_( 0.05_CD M_NP sodium_NN citrate_NN ,_, 0.5_CD M_NP sodium_NN hydroxide_NN )_) was_VBD added_VBN ._SENT After_IN centrifugation_NN (_( at_IN 28,800_CD x_NN g_NN for_IN 2_CD min_NN )_) the_DT supernatant_JJ was_VBD discarded_VBN ._SENT Approximately_RB 500_CD mul_NN of_IN 0.5_CD M_NP Tris_NP HCl_NP (_( pH_NN 8.0_CD )_) buffer_NN was_VBD added_VBN ._SENT After_IN centrifugation_NN the_DT supernatant_JJ was_VBD discarded_VBN and_CC 100_CD mul_NN of_IN sterile_JJ distilled_JJ water_NN was_VBD added_VBN ._SENT The_DT tube_NN was_VBD incubated_VBN at_IN 95C_NN for_IN 15_CD min_NN ._SENT The_DT following_VBG oligonucleotide_NN primers_NNS whose_WP$ sequences_NNS are_VBP specific_JJ for_IN sequences_NNS flanking_VBG the_DT katG_NN gene_NN (_( GenBank_NP database_NN accession_NN number_NN )_) were_VBD used_VBN as_IN primers_NNS in_IN the_DT PCR_NP :_: KatG_NP 5_CD '_'' (_( 5'-CCGACACTTCGCGATCACATCCGTGATCACAGCCC-3_NP '_POS )_) and_CC KatG_NP 3_CD '_'' (_( 5-GGTGCTGCGGCGGGTTGTGGTTGATCGG-3_NP '_POS )_) ._SENT The_DT PCR_NP was_VBD carried_VBN out_RP with_IN a_DT 50-mul_NP reaction_NN volume_NN containing_VBG PCR_NP buffer_NN ,_, genomic_JJ DNA_NN (_( 2_CD mul_NN )_) ,_, 1.1_CD mM_NP magnesium_NN diacetate_NN ,_, 200_CD muM_NN deoxynucleoside_NN triphosphates_NNS ,_, each_DT primer_NN at_IN a_DT concentration_NN of_IN 0.2_CD muM_NN ,_, and_CC 1_CD U_NN of_IN rTth_JJ DNA_NN polymerase_NN (_( GeneAmp_NP XL_NP PCR_NP kit_NN ;_: Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) ._SENT The_DT mixture_NN was_VBD overlaid_VBN with_IN AmpliWax_NP PCR_NP Gem_NP (_( Applied_NP Biosystems_NP )_) and_CC heated_VBN for_IN 1_CD min_NN at_IN 94C_NN ,_, followed_VBN by_IN 35_CD cycles_NNS of_IN 1_CD min_NN at_IN 94C_NN and_CC 2.5_CD min_NN at_IN 72C_NP ._SENT A_DT single_JJ 2,200-bp_JJ band_NN corresponding_JJ to_TO the_DT amplified_VBN product_NN was_VBD detected_VBN by_IN ethidium_NN bromide_NN staining_VBG after_IN electrophoresis_NN on_IN 0.9_CD %_NN (_( wt/vol_NN )_) agarose_NN ._SENT The_DT PCR_NP product_NN was_VBD prepared_VBN for_IN sequencing_VBG by_IN treatment_NN with_IN shrimp_NN alkaline_JJ phosphatase_NN to_TO dephosphorylate_VB all_DT remaining_VBG deoxynucleoside_NN triphosphates_NNS and_CC with_IN exonuclease_NN I_PP to_TO degrade_VB all_DT residual_JJ single-stranded_JJ DNA_NN present_NN in_IN the_DT PCR_NP mixture_NN ._SENT The_DT entire_JJ katG_NN gene_NN was_VBD sequenced_VBN with_IN the_DT ABI_NP PRISM_NP Big_NP Dye_NP Terminator_NP Cycle_NP Sequencing_NP Ready_JJ Reaction_NN kit_NN with_IN AmpliTaq_NP DNA_NP polymerase_NN on_IN an_DT ABI_NP PRISM_NN 377_CD DNA_NN sequencer_NN with_IN XL_NP Upgrade_NP and_CC 96-well_NP Upgrade_NP (_( Perkin-Elmer_NP Applied_NP Biosystems_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) by_IN using_VBG eight_CD primers_NNS whose_WP$ sequences_NNS were_VBD specific_JJ for_IN sequences_NNS that_WDT spanned_VBD the_DT length_NN of_IN the_DT gene_NN (_( the_DT primers_NNS and_CC their_PP$ sequences_NNS are_VBP presented_VBN in_IN the_DT Appendix_NN )_) ._SENT The_DT sequence_NN data_NNS assembled_VBN with_IN the_DT Sequencher_NP program_NN (_( Gene_NP Codes_NP Inc._NP )_) confirmed_VBD the_DT presence_NN of_IN the_DT S315T_NP mutation_NN and_CC the_DT absence_NN of_IN secondary_JJ mutations_NNS ._SENT Susceptibility_NN testing_NN ._SENT |_SYM The_DT susceptibilities_NNS of_IN M._NP tuberculosis_NN H37Rv_NP and_CC TBC3_NP to_TO INH_NP alone_RB and_CC INH_NP in_IN combination_NN with_IN plumbagin_NP and_CC clofazimine_NP were_VBD determined_VBN by_IN using_VBG the_DT radiometric_JJ criteria_NNS of_IN the_DT BACTEC_NP 460_CD system_NN (_( Becton_NP Dickinson_NP ,_, Sparks_NP ,_, Md._NP )_) ._SENT All_DT procedures_NNS were_VBD carried_VBN out_RP in_IN a_DT biological_JJ safety_NN cabinet_NN inside_IN a_DT biosafety_NN level_NN 3_CD biocontainment_NN facility_NN ._SENT Studies_NNS involving_VBG combinations_NNS of_IN drugs_NNS were_VBD carried_VBN out_RP with_IN weakly_JJ inhibitory_JJ concentrations_NNS of_IN clofazimine_NN and_CC plumbagin_NP ,_, as_RB determined_VBN by_IN use_NN of_IN the_DT radiometric_JJ criteria_NNS ._SENT According_VBG to_TO the_DT instructions_NNS of_IN the_DT manufacturer_NN (_( S._NP H._NP Siddiqi_NP ,_, BACTEC_NP 460TB_JJ system_NN ,_, product_NN and_CC procedure_NN manual_NN ,_, 1995_CD ,_, Becton_NP Dickinson_NP ,_, Sparks_NP ,_, Md._NP )_) ,_, a_DT suspension_NN of_IN an_DT actively_RB growing_VBG culture_NN was_VBD made_VBN in_IN water_NN ,_, and_CC 0.1_CD ml_NN was_VBD transferred_VBN to_TO a_DT BACTEC_NP 12B_JJ bottle_NN ._SENT These_DT bottles_NNS were_VBD incubated_VBN until_IN the_DT appropriate_JJ growth_NN index_NN (_( GI_NP )_) was_VBD obtained_VBN ,_, after_IN which_WDT 0.1-ml_NN aliquots_NNS were_VBD removed_VBN and_CC transferred_VBN to_TO fresh_JJ BACTEC_NP 12B_JJ bottles_NNS containing_VBG drugs_NNS ._SENT The_DT bottles_NNS were_VBD incubated_VBN at_IN 37C_JJ and_CC analyzed_VBD daily_RB until_IN the_DT GI_NP of_IN the_DT growth_NN control_NN diluted_JJ 1:100_CD was_VBD >=30_JJ ._SENT Resistance_NN was_VBD determined_VBN by_IN comparing_VBG the_DT change_NN in_IN GI_NP over_IN that_DT of_IN the_DT previous_JJ day_NN (_( DeltaGI_NP )_) between_IN the_DT control_NN vial_NN (_( GIcontrol_NP )_) and_CC the_DT vials_NNS containing_VBG drugs_NNS (_( GIdrugs_NP )_) ._SENT The_DT results_NNS are_VBP interpreted_VBN as_RB follows_VBZ :_: if_IN DeltaGIcontrol_NP is_VBZ >DeltaGIdrug_NN ,_, the_DT strain_NN is_VBZ referred_VBN to_TO as_RB "_`` susceptible_JJ "_'' ;_: if_IN DeltaGIcontrol_NP is_VBZ <DeltaGIdrug,_the =30_JJ ,_, and_CC corresponds_VBZ to_TO the_DT daily_JJ concentration_NN that_WDT resulted_VBD in_IN >99_JJ %_NN inhibition_NN of_IN the_DT bacterial_JJ population_NN growth_NN ._SENT The_DT IC50_NP corresponds_VBZ to_TO the_DT concentration_NN of_IN drug_NN that_WDT causes_VBZ a_DT 50_CD %_NN decrease_NN in_IN the_DT GI_NP ._SENT The_DT IC50s_NP of_IN INH_NP were_VBD obtained_VBN by_IN least-squares_NNS fitting_VBG of_IN the_DT data_NNS to_TO the_DT Langmuir_NP isotherm_NN equation_NN :_: B_SYM =_SYM 1/[1_JJ +_SYM (_( IC50/[INH_NP ]_SYM )_) ]_SYM ,_, where_WRB B_NP is_VBZ equal_JJ to_TO percent_NN GI/100_NP %_NN ._SENT The_DT percent_NN reduction_NN of_IN the_DT IC50_NP of_IN INH_NP in_IN the_DT presence_NN of_IN clofazimine_NP and_CC plumbagin_NP is_VBZ determined_VBN by_IN the_DT following_VBG equation_NN :_: {_( [_SYM IC50(INH)_NP -_: IC50(X)]/IC50(INH)_NP }_) x_SYM 100_CD ,_, where_WRB IC50(INH)_NP and_CC IC50(X)_NP represent_VBP the_DT IC50s_NP of_IN INH_NP in_IN the_DT absence_NN and_CC presence_NN of_IN plumbagin_NP or_CC clofazimine_NP ,_, respectively_RB ._SENT The_DT relative_JJ error_NN was_VBD calculated_VBN by_IN applying_VBG the_DT basic_JJ theory_NN of_IN error_NN :_: [_SYM IC50(X)/IC50(INH)_NP ]_SYM x_NN {_( [_SYM DeltaIC50(INH)/IC50(INH)_NP ]_SYM +_SYM [_SYM DeltaIC50(X)/IC50(X)_NP ]_SYM }_) ,_, where_WRB DeltaIC50(INH)_NP represents_VBZ the_DT error_NN of_IN determination_NN of_IN the_DT IC50_NP of_IN INH_NP ,_, and_CC DeltaIC50(X)_NP is_VBZ the_DT error_NN of_IN determination_NN of_IN the_DT IC50_NP of_IN INH_NP in_IN the_DT presence_NN of_IN plumbagin_NP or_CC clofazimine_NP ._SENT The_DT effect_NN of_IN the_DT superoxide-generating_VBG compounds_NNS plumbagin_NNS and_CC clofazimine_NN on_IN the_DT activity_NN of_IN INH_NP against_IN M._NP tuberculosis_NN strains_NNS H37Rv_NP and_CC TBC3_NP was_VBD assessed_VBN by_IN use_NN of_IN the_DT BACTEC_NP radiometric_JJ criteria_NNS ._SENT DeltaGI_NP values_NNS for_IN cultures_NNS of_IN these_DT strains_NNS in_IN the_DT presence_NN of_IN INH_NP alone_RB were_VBD determined_VBN ._SENT The_DT range_NN of_IN INH_NP concentrations_NNS chosen_VBN allows_VBZ accurate_JJ determination_NN of_IN the_DT MIC_NP of_IN INH_NP for_IN a_DT strain_NN with_IN wild-type_NN katG_NN (_( strain_NN H37Rv_NP )_) and_CC a_DT strain_NN with_IN katG_NN harboring_VBG the_DT S315T_NP mutation_NN (_( strain_NN TBC3_NP )_) ._SENT The_DT MIC_NP of_IN INH_NP for_IN TBC3_NP was_VBD 5_CD mug/ml_NN ,_, 200-fold_NN higher_JJR than_IN the_DT MIC_NP for_IN H37Rv_NP (_( 0.025_CD mug/ml_NN )_) ,_, confirming_VBG the_DT efficacy_NN of_IN the_DT S315T_NP mutation_NN in_IN conferring_VBG resistance_NN to_TO INH_NP ._SENT It_PP should_MD be_VB noted_VBN that_IN TBC3_NP is_VBZ not_RB an_DT isogenic_JJ mutant_NN of_IN H37Rv_NP ._SENT Therefore_RB ,_, genotypic_JJ differences_NNS other_JJ than_IN the_DT S315T_NP mutation_NN that_WDT could_MD contribute_VB to_TO the_DT increased_VBN MIC_NN cannot_MD be_VB excluded_VBN ._SENT The_DT susceptibilities_NNS of_IN H37Rv_NP and_CC TBC3_NP to_TO clofazimine_NP and_CC plumbagin_NP alone_RB were_VBD determined_VBN as_RB well_RB ._SENT For_IN both_DT strains_NNS ,_, the_DT MIC_NN of_IN clofazimine_NN was_VBD >0.1_JJ mug/ml_NN but_CC <=0.2_mug/ml, =0.1_JJ mug/ml_NN ._SENT This_DT is_VBZ in_IN agreement_NN with_IN previous_JJ studies_NNS ,_, which_WDT showed_VBD a_DT MIC_NN of_IN 0.12_CD mug/ml_NN ._SENT A_DT concentration_NN of_IN 0.1_CD mug_NN of_IN clofazimine_NN per_IN ml_NN was_VBD therefore_RB chosen_VBN as_IN the_DT subinhibitory_JJ concentration_NN to_TO be_VB used_VBN in_IN combination_NN with_IN INH_NP (_( see_VB below_IN )_) ._SENT Plumbagin_NP also_RB caused_VBD a_DT decline_NN in_IN the_DT GI_JJ values_NNS for_IN both_DT strains_NNS ,_, with_IN noticeable_JJ decreases_NNS in_IN the_DT GI_JJ values_NNS at_IN 10_CD to_TO 20_CD muM_NN ._SENT TBC3_NP appeared_VBD to_TO be_VB slightly_RB more_RBR sensitive_JJ to_TO plumbagin_NP ,_, with_IN a_DT slight_JJ (_( ~30_JJ %_NN )_) decline_NN in_IN the_DT GI_JJ value_NN by_IN day_NN 7_CD in_IN the_DT presence_NN of_IN 10_CD muM_NN plumbagin_NN ,_, whereas_IN for_IN H37Rv_NP ,_, 20_CD muM_NN plumbagin_NP led_VBD to_TO a_DT similar_JJ ,_, modest_JJ decrease_NN in_IN the_DT GI_JJ value_NN ._SENT As_IN a_DT result_NN ,_, the_DT subinhibitory_JJ concentrations_NNS of_IN plumbagin_NP were_VBD chosen_VBN to_TO be_VB 20_CD muM_NN for_IN H37Rv_NP and_CC 10_CD muM_NN for_IN TBC3_NP ._SENT The_DT influences_NNS of_IN subinhibitory_JJ concentrations_NNS of_IN clofazimine_NN and_CC plumbagin_NN on_IN susceptibility_NN to_TO INH_NP were_VBD assessed_VBN by_IN analysis_NN with_IN the_DT BACTEC_NP system_NN ._SENT Both_DT compounds_NNS led_VBN to_TO significant_JJ increases_NNS in_IN the_DT susceptibility_NN of_IN wild-type_NN strain_NN H37Rv_NP to_TO INH_NP (_( Fig._NN ;_: Table_NP )_) ._SENT The_DT MIC_NP of_IN INH_NP decreased_VBD from_IN 0.025_CD mug/ml_NN (_( with_IN INH_NP alone_RB )_) to_TO 0.012_CD mug/ml_NN in_IN the_DT presence_NN of_IN 0.1_CD mug_NN of_IN clofazimine_NN per_IN ml_NN and_CC to_TO 0.008_CD mug/ml_NN in_IN the_DT presence_NN of_IN 20_CD muM_NN plumbagin_NN ._SENT Susceptibility_NN was_VBD also_RB assessed_VBN by_IN estimating_VBG the_DT IC50_NP of_IN INH_NP ._SENT The_DT IC50_NP ,_, being_VBG the_DT concentration_NN of_IN drug_NN that_WDT causes_VBZ a_DT 50_CD %_NN decrease_NN in_IN GI_NP ,_, is_VBZ a_DT more_RBR sensitive_JJ measure_NN of_IN the_DT effects_NNS of_IN these_DT agents_NNS than_IN the_DT MIC_NP ,_, which_WDT is_VBZ the_DT lowest_JJS concentration_NN of_IN drug_NN that_IN results_NNS in_IN a_DT >99_JJ %_NN decrease_NN in_IN cell_NN growth_NN ._SENT IC50s_NNS were_VBD determined_VBN by_IN a_DT least-squares_NNS fit_VBP of_IN the_DT data_NNS presented_VBN in_IN Fig._NN ,_, as_RB described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT The_DT IC50_NP of_IN INH_NP was_VBD found_VBN to_TO be_VB 0.015_CD +-_NN 0.007_CD mug/ml_NN (_( Fig._NN ,_, top_JJ )_) ,_, decreasing_VBG twofold_JJ (_( to_TO 0.0068_CD +-_NN 0.0015_CD mug/ml_NN )_) in_IN the_DT presence_NN of_IN 20_CD muM_NN plumbagin_NP (_( Fig._NN ,_, middle_JJ )_) and_CC decreasing_VBG about_RB 30_CD %_NN (_( to_TO 0.0099_CD +-_NN 0.0026_CD mug/ml_NN )_) in_IN the_DT presence_NN of_IN 0.1_CD mug_NN of_IN clofazimine_NN per_IN ml_NN (_( Fig._NN ,_, bottom_JJ )_) ._SENT The_DT activity_NN of_IN INH_NP alone_RB or_CC in_IN combination_NN with_IN plumbagin_NP (_( 10_CD muM_NN )_) or_CC clofazimine_JJ (_( 0.1_CD mug/ml_NN )_) against_IN TBC3_NP was_VBD also_RB investigated_VBN (_( Table_NP ;_: Fig._NN )_) ._SENT Both_CC the_DT MIC_NP and_CC the_DT IC50_NP of_IN INH_NP also_RB appeared_VBD to_TO decrease_VB in_IN the_DT presence_NN of_IN these_DT compounds_NNS ._SENT With_IN INH_NP alone_RB ,_, the_DT IC50_NP was_VBD 2.1_CD +-_NN 0.7_CD mug/ml_NN ,_, whereas_IN in_IN the_DT presence_NN of_IN plumbagin_NP or_CC clofazimine_NP ,_, the_DT IC50s_NP were_VBD 1.3_CD +-_NN 0.5_CD and_CC 1.5_CD +-_NN 1.2_CD mug/ml_NN ,_, respectively_RB ._SENT Compared_VBN to_TO the_DT reductions_NNS in_IN the_DT IC50s_NP of_IN INH_NP in_IN combination_NN with_IN plumbagin_NP or_CC clofazimine_NN for_IN strain_NN H37Rv_NP (_( 55_CD and_CC 34_CD %_NN ,_, respectively_RB )_) ,_, the_DT reductions_NNS in_IN the_DT IC50s_NP for_IN TBC3_NP were_VBD lower_JJR ._SENT For_IN TBC3_NP ,_, the_DT corresponding_JJ decreases_NNS were_VBD 38_CD and_CC 28_CD %_NN ._SENT FIG._NN 1_CD ._SENT |_SYM INH_NP susceptibilities_NNS of_IN M._NP tuberculosis_NN INH_NP susceptibilities_NNS of_IN M._NP tuberculosis_NN (_( Mtb_NP )_) strains_VBZ H37Rv_NP (_( A_NP )_) and_CC TBC3_NP (_( B_NP )_) using_VBG BACTEC_NP radiometric_JJ analysis_NN ._SENT The_DT control_NN reaction_NN represents_VBZ that_IN in_IN a_DT vial_NN containing_VBG a_DT starter_JJ culture_NN diluted_VBD 1:100_CD relative_NN to_TO the_DT inoculum_NN in_IN the_DT vials_NNS containing_VBG INH_NP ._SENT The_DT asterisks_NNS indicate_VBP the_DT MICs_NP of_IN INH_NP for_IN each_DT strain_NN ,_, as_RB defined_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT GI_NP data_NNS were_VBD obtained_VBN on_IN a_DT daily_JJ basis_NN following_VBG inoculation_NN of_IN BACTEC_NP vials_NNS ,_, but_CC data_NNS for_IN only_JJ selective_JJ days_NNS are_VBP shown_VBN for_IN clarity_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Susceptibilities_NP of_IN M._NP tuberculosis_NN Susceptibilities_NNS of_IN M._NP tuberculosis_NN (_( Mtb_NP )_) H37Rv_NP (_( A_NP )_) and_CC TBC3_NP (_( B_NP )_) to_TO plumbagin_NP and_CC clofazimine_NP ._SENT FIG._NN 3_CD ._SENT |_SYM Effects_NN of_IN plumbagin_NP and_CC clofazimine_NN on_IN INH_NP susceptibility_NN ._SENT Effects_NNS of_IN plumbagin_NP and_CC clofazimine_NN on_IN INH_NP susceptibility_NN ._SENT The_DT percent_NN GI_NN is_VBZ plotted_VBN versus_IN the_DT log[INH_NN ]_SYM (_( p[INH_NP ]_SYM )_) ,_, expressed_VBN in_IN units_NNS of_IN nanograms_NNS per_IN milliliter_NN ,_, alone_RB (_( top_JJ )_) or_CC in_IN the_DT presence_NN of_IN plumbagin_NP (_( middle_NN )_) or_CC clofazimine_JJ (_( bottom_NN )_) ,_, for_IN M._NP tuberculosis_NN H37Rv_NP (_( A_NP )_) and_CC TBC3_NP (_( B_NP )_) ._SENT Weakly_JJ inhibitory_JJ concentration_NN of_IN clofazimine_NN (_( 0.1_CD mug/ml_NN )_) and_CC plumbagin_NP (_( 20_CD muM_NN in_IN panels_NNS A_NP ,_, 10_CD muM_NN in_IN panels_NNS B_NP )_) were_VBD included_VBN in_IN each_DT vial_NN ._SENT IC50s_NNS were_VBD calculated_VBN for_IN each_DT graph_NN as_IN the_DT concentration_NN of_IN INH_NP resulting_VBG in_IN a_DT 50_CD %_NN decrease_NN in_IN the_DT GI_JJ value_NN relative_JJ to_TO that_DT for_IN the_DT control_NN vials_NNS ,_, as_RB described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT The_DT vertical_JJ dotted_JJ line_NN in_IN each_DT set_NN of_IN panels_NNS represents_VBZ the_DT IC50_NP of_IN INH_NP alone_RB (_( 0.015_CD mug/ml_NN in_IN panels_NNS A_NP ,_, 2.1_CD mug/ml_NN in_IN panels_NNS B_NN )_) ._SENT (_( C_NP )_) Reduction_NP of_IN IC50_NP of_IN INH_NP for_IN H37Rv_NP and_CC TBC3_NP by_IN plumbagin_NP and_CC clofazimine_NP ._SENT The_DT percent_NN GI_NN is_VBZ expressed_VBN as_IN the_DT average_JJ value_NN +-_NN the_DT standard_JJ error_NN for_IN three_CD experiments_NNS ._SENT TABLE_NN 1_CD |_SYM MICs_NP of_IN INH_NP used_VBD alone_RB and_CC in_IN combination_NN with_IN plumbagin_NP or_CC clofazimine_NN for_IN M._NP tuberculosis_NN strains_NNS H37Rv_NP and_CC TBC3_NP Although_IN a_DT role_NN for_IN KatG_NP in_IN mediating_VBG INH_NP activation_NN is_VBZ firmly_RB established_VBN ,_, the_DT mechanism_NN of_IN activation_NN and_CC the_DT chemical_JJ nature_NN of_IN the_DT activated_VBN product_NN are_VBP still_RB unresolved_JJ ._SENT Initially_RB described_VBN as_IN a_DT catalase-peroxidase_NN on_IN the_DT basis_NN of_IN the_DT homology_NN of_IN its_PP$ amino_NN acid_NN sequence_NN to_TO that_DT of_IN the_DT Escherichia_NP coli_NNS hydroperoxidase_NN I_CD enzyme_NN ,_, the_DT enzyme_NN has_VBZ subsequently_RB been_VBN shown_VBN to_TO exhibit_VB a_DT number_NN of_IN different_JJ catalytic_JJ activities_NNS ._SENT Three_CD of_IN these_DT ,_, the_DT catalase_NN ,_, peroxidase_NN ,_, and_CC Mn2+-dependent_JJ peroxidase_NN activities_NNS ,_, share_VBP a_DT common_JJ mechanism_NN in_IN which_WDT a_DT hydroperoxide_NN substrate_NN (_( e.g._FW ,_, H2O2_NP and_CC tert-butylhydroperoxide_NN )_) oxidizes_VBZ the_DT Fe3+_NP form_NN of_IN the_DT enzyme_NN and_CC forms_VBZ an_DT intermediate_JJ ,_, compound_VB I_PP ,_, which_WDT is_VBZ 2_CD equivalents_NNS more_RBR oxidized_VBN than_IN the_DT resting_JJ enzyme_NN ._SENT Compound_VB I_PP ,_, in_IN turn_NN ,_, oxidizes_VBZ a_DT second_JJ substrate_NN (_( e.g._FW ,_, INH_NP )_) ,_, returning_VBG the_DT enzyme_NN to_TO the_DT resting_JJ ferric_JJ state_NN ._SENT The_DT initial_JJ hypothesis_NN that_IN the_DT S315T_NP mutation_NN might_MD confer_VB resistance_NN to_TO M._NP tuberculosis_NN by_IN affecting_VBG the_DT catalase-peroxidase_NN mechanism_NN was_VBD tested_VBN by_IN comparing_VBG these_DT activities_NNS for_IN recombinant_JJ forms_NNS of_IN the_DT wild-type_NN and_CC S315T_NP enzymes_NNS ._SENT These_DT studies_NNS demonstrated_VBD that_IN the_DT catalytic_JJ efficiency_NN of_IN KatG(S315T)_NP is_VBZ comparable_JJ to_TO or_CC only_RB slightly_RB lower_JJR than_IN the_DT catalytic_JJ efficiency_NN of_IN the_DT wild-type_NN enzyme_NN for_IN all_DT three_CD activities_NNS and_CC does_VBZ not_RB correlate_VB with_IN the_DT ca_MD ._SENT 200-fold_JJ difference_NN in_IN the_DT MICs_NP of_IN INH_NP for_IN strains_NNS carrying_VBG wild-type_NN versus_IN S315T_NP katG_NN alleles_NNS ,_, as_RB measured_VBN in_IN this_DT and_CC other_JJ studies_NNS ._SENT It_PP has_VBZ been_VBN shown_VBN that_IN KatG-mediated_NP INH_NP activation_NN is_VBZ probably_RB not_RB by_IN direct_JJ peroxidation_NN ,_, as_IN the_DT enzyme_NN catalyzes_VBZ INH_NP oxidation_NN in_IN the_DT absence_NN of_IN peroxide_NN ._SENT An_DT alternative_JJ mechanism_NN for_IN KatG-dependent_NP INH_NP turnover_NN ,_, in_IN which_WDT dioxygen_NN is_VBZ used_VBN as_IN the_DT oxidant_NN ,_, has_VBZ gained_VBN attention_NN in_IN recent_JJ years_NNS (_( -_: ,_, )_) ._SENT The_DT mechanism_NN for_IN this_DT reaction_NN is_VBZ not_RB completely_RB understood_VBN but_CC is_VBZ thought_VBN to_TO proceed_VB in_IN a_DT manner_NN analogous_JJ to_TO those_DT for_IN cytochromes_NNS P450_JJ ._SENT In_IN this_DT reaction_NN ,_, dioxygen_NN binds_NNS to_TO the_DT Fe2+_NP form_NN of_IN KatG_NP to_TO form_VB an_DT oxyferrous_JJ intermediate_NN ,_, which_WDT goes_VBZ on_RP to_TO form_VB a_DT compound_JJ I-type_NN species_NNS after_IN an_DT additional_JJ redox_NN reaction_NN (_( -_: ,_, )_) ._SENT The_DT oxyferrous_JJ enzyme_NN is_VBZ a_DT resonance_NN form_NN of_IN the_DT ferric-superoxo_NN enzyme_NN ._SENT Consequently_RB ,_, the_DT oxyferrous_JJ intermediate_NN can_MD also_RB form_VB by_IN reaction_NN of_IN superoxide_NN anion_NN with_IN the_DT Fe3+_NP form_NN of_IN KatG_NP ._SENT On_IN the_DT basis_NN of_IN the_DT observation_NN that_IN KatG-dependent_NP activation_NN of_IN INH_NP generates_VBZ reactive_JJ oxygen_NN species_NNS (_( ,_, -_: )_) ,_, it_PP has_VBZ been_VBN hypothesized_VBN that_DT superoxide_NN ,_, formed_VBN via_IN a_DT one-electron_NN reduction_NN of_IN dioxygen_NN concomitant_NN with_IN INH_NP oxidation_NN ,_, can_MD bind_VB to_TO the_DT ferric_JJ heme_NN to_TO form_VB oxyferrous_JJ KatG_NP and_CC bring_VB about_RB further_JJR INH_NP oxidation_NN and_CC activation_NN ._SENT Support_NN for_IN the_DT physiological_JJ relevance_NN of_IN this_DT mechanism_NN was_VBD provided_VBN by_IN Wang_NP et_FW al._FW ,_, who_WP showed_VBD that_IN the_DT superoxide_NN generator_NN plumbagin_NP resulted_VBD in_IN an_DT increase_NN in_IN the_DT bacteriostatic_JJ activity_NN of_IN INH_NP against_IN M._NP smegmatis_NP ,_, a_DT strain_NN normally_RB resistant_JJ to_TO INH_NP ._SENT Other_JJ supporting_JJ experiments_NNS have_VBP shown_VBN that_IN KatG(S315T)_NP has_VBZ a_DT reduced_VBN ability_NN to_TO oxidize_VB INH_NP to_TO isonicotinic_JJ acid_NN when_WRB superoxide_NN is_VBZ used_VBN as_IN the_DT oxidant_NN ._SENT In_IN this_DT work_NN ,_, the_DT role_NN of_IN superoxide_NN anion_NN in_IN INH_NP oxidation_NN in_IN vivo_RB was_VBD investigated_VBN by_IN radiometric_JJ analysis_NN of_IN INH_NP susceptibility_NN in_IN the_DT presence_NN versus_IN the_DT absence_NN of_IN plumbagin_NP and_CC clofazimine_NP ._SENT Plumbagin_NP is_VBZ a_DT known_JJ redox_NN cycling_NN agent_NN expected_VBN to_TO increase_VB intracellular_JJ superoxide_NN concentrations_NNS ._SENT The_DT precise_JJ mechanism_NN of_IN action_NN of_IN clofazimine_NN is_VBZ unknown_JJ ,_, but_CC it_PP has_VBZ been_VBN suggested_VBN that_IN it_PP generates_VBZ intracellular_JJ hydrogen_NN peroxide_NN and_CC superoxide_NN ._SENT Clofazimine_NP has_VBZ been_VBN used_VBN for_IN the_DT treatment_NN of_IN leprosy_NN and_CC has_VBZ excellent_JJ in_IN vitro_NP inhibitory_JJ activity_NN against_IN M._NP avium-M_NN ._SENT intracellulare_JJ complex_JJ strains_NNS ,_, with_IN MICs_NNS that_WDT range_VBP from_IN 0.1_CD to_TO 5_CD mug/ml_NN ._SENT The_DT drug_NN also_RB has_VBZ potent_JJ in_IN vitro_NN activity_NN against_IN M._NP tuberculosis_NN ,_, but_CC there_EX is_VBZ little_JJ or_CC no_DT information_NN on_IN its_PP$ in_IN vivo_JJ activity_NN ._SENT The_DT M._NP tuberculosis_NN strain_NN carrying_VBG the_DT wild-type_NN katG_NN allele_NN ,_, strain_NN H37Rv_NP ,_, exhibited_VBD increased_VBN susceptibility_NN to_TO INH_NP when_WRB INH_NP was_VBD used_VBN in_IN combination_NN with_IN either_DT plumbagin_NP or_CC clofazimine_NP ,_, as_RB evidenced_VBN by_IN a_DT decrease_NN in_IN both_CC the_DT IC50s_NP and_CC the_DT MICs_NP of_IN INH_NP in_IN the_DT presence_NN of_IN these_DT reagents_NNS ._SENT Hence_RB ,_, a_DT superoxide-dependent_JJ mechanism_NN appears_VBZ to_TO be_VB important_JJ for_IN KatG-mediated_NP INH_NP activation_NN in_IN this_DT strain_NN ._SENT KatG(S315T)_NP also_RB appears_VBZ to_TO utilize_VB superoxide_NN to_TO activate_VB INH_NP ,_, as_RB evidenced_VBN by_IN the_DT fact_NN that_IN INH_NP turnover_NN by_IN the_DT purified_VBN enzyme_NN is_VBZ completely_RB abolished_VBN in_IN the_DT presence_NN of_IN a_DT catalytic_JJ quantity_NN of_IN superoxide_NN dismutase_NN (_( SOD_NP )_) ._SENT Indeed_RB ,_, although_IN the_DT potency_NN of_IN INH_NP was_VBD increased_VBN by_IN a_DT putative_JJ increase_NN in_IN superoxide_NN production_NN by_IN plumbagin_NP and_CC clofazimine_NN in_IN INH-resistant_JJ strain_NN TBC3_NP ,_, our_PP$ data_NNS indicate_VBP that_IN the_DT katG_NN S315T_NP mutation_NN attenuates_VBZ this_DT activation_NN ._SENT Thus_RB ,_, KatG-mediated_NP INH_NP oxidative_JJ activation_NN is_VBZ superoxide_NN dependent_JJ in_IN M._NP tuberculosis_NN and_CC the_DT S315T_NP mutation_NN may_MD confer_VB an_DT INH_NP resistance_NN phenotype_NN through_IN a_DT reduced_VBN activity_NN toward_IN superoxide_NN ._SENT Although_IN the_DT results_NNS implicate_VBP superoxide_NN potentiation_NN of_IN INH_NP toxicity_NN in_IN both_DT strains_NNS ,_, H37Rv_NP appeared_VBD to_TO be_VB more_RBR sensitive_JJ to_TO increased_VBN levels_NNS of_IN superoxide_NN than_IN TBC3_NP ._SENT The_DT hypothesis_NN that_IN superoxide_NN participates_VBZ in_IN the_DT KatG-mediated_NP INH_NP oxidation_NN is_VBZ intriguing_JJ because_IN M._NP tuberculosis_NN contains_VBZ both_DT ferric_JJ and_CC Cu,Zn_NP SODs_NP ._SENT Superoxide-dependent_JJ activation_NN may_MD be_VB possible_JJ only_RB because_IN all_DT of_IN the_DT Cu,Zn_NP SOD_NP and_CC 76_CD %_NN of_IN the_DT ferric_JJ SOD_NN are_VBP exported_VBN from_IN the_DT cell_NN ,_, presumably_RB to_TO act_VB as_IN extracellular_JJ defenses_NNS against_IN the_DT host_NN respiratory_JJ burst_NN ._SENT The_DT potential_JJ chemical_NN implications_NNS of_IN these_DT findings_NNS are_VBP intriguing_JJ ._SENT It_PP is_VBZ possible_JJ that_IN clofazimine_NN in_IN combination_NN with_IN INH_NP may_MD result_VB in_IN synergistic_JJ activity_NN in_IN vitro_NN against_IN M._NP tuberculosis_NN ._SENT This_DT synergistic_JJ activity_NN may_MD be_VB more_JJR for_IN the_DT wild-type_JJ M._NP tuberculosis_NN strain_NN than_IN for_IN strains_NNS harboring_VBG the_DT katG_NN S315T_NP mutation_NN ._SENT Further_RBR animal_JJ and_CC human_JJ studies_NNS are_VBP required_VBN to_TO validate_VB these_DT assumptions_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM The_DT INH_NP shunt_NN ,_, a_DT proposed_VBN mechanism_NN for_IN INH_NP oxidation_NN by_IN ferric_JJ superoxo-KatG_NN ._SENT The_DT INH_NP shunt_NN ,_, a_DT proposed_VBN mechanism_NN for_IN INH_NP oxidation_NN by_IN ferric_JJ superoxo-KatG_NN ._SENT The_DT following_VBG primers_NNS were_VBD used_VBN for_IN sequencing_NP :_: KatG_NP 5_CD '_POS ,_, CCG_NP ACA_NP CTT_NP CGC_NP GAT_NP CAC_NP ATC_NP CGT_NP GAT_NP CAC_NP AGC_NP CC_NP ;_: KatG_NP 2_CD ,_, ATG_NP ACC_NP ACC_NP TCG_NP CAG_NP CCG_NP ;_: KatG_NP 3_CD ,_, GGC_NP TTC_NP GGC_NP CGG_NP GTC_NP GAC_NP ;_: KatG_NP 4_CD ,_, GTC_NP GGC_NP CCC_NP GAA_NP CCC_NP GAG_NP ;_: KatG_NP 5_CD ,_, CTG_NP CGG_NP GTG_NP GAT_NP CCG_NP ATC_NP ;_: KatG_NP 6_CD ,_, CGT_NP GGT_NP AGC_NP GAC_NP AAG_NP CGC_NP ;_: KatG_NP 7_CD ,_, TTT_NP GCC_NP GTG_NP CTG_NP GAG_NP CCC_NP ;_: KatG_NP 8_CD ,_, AGT_NP GGC_NP AAG_NP GTG_NP AAG_NP TGG_NP ;_: and_CC KatG_NP 2_CD '_POS reverse_JJ primer_NN ,_, CCG_NP TAG_NP TCG_NP GCG_NP GGC_NP CAC_NP CAC_NP GGC_NP T._NP 